MCL1 and central nervous system cancer: However, ABT-737 was less efficient in glioma stem cells with high myeloid cell leukemia 1 (MCL1) expression, and sorafenib targeting MCL1 synergized with ABT-737 to trigger apoptotic cell death in glioma cells (81).